KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Change in Inventory (2017 - 2025)

Historic Change in Inventory for BeOne Medicines (ONC) over the last 9 years, with Q3 2025 value amounting to $28.8 million.

  • BeOne Medicines' Change in Inventory rose 22097.16% to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.0 million, marking a year-over-year increase of 134.77%. This contributed to the annual value of $91.5 million for FY2024, which is 3508.53% down from last year.
  • Per BeOne Medicines' latest filing, its Change in Inventory stood at $28.8 million for Q3 2025, which was up 22097.16% from -$2.2 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Change in Inventory ranged from a high of $91.6 million in Q4 2021 and a low of -$23.8 million during Q3 2024
  • In the last 5 years, BeOne Medicines' Change in Inventory had a median value of $28.6 million in 2022 and averaged $24.5 million.
  • The largest annual percentage gain for BeOne Medicines' Change in Inventory in the last 5 years was 135752.95% (2021), contrasted with its biggest fall of 745090.09% (2021).
  • BeOne Medicines' Change in Inventory (Quarter) stood at $91.6 million in 2021, then crashed by 120.67% to -$18.9 million in 2022, then soared by 567.6% to $88.6 million in 2023, then decreased by 10.38% to $79.4 million in 2024, then crashed by 63.68% to $28.8 million in 2025.
  • Its Change in Inventory was $28.8 million in Q3 2025, compared to -$2.2 million in Q2 2025 and -$4.0 million in Q1 2025.